Transgene SA (EPA:TNG)
France · Delayed Price · Currency is EUR 0.7550
-0.0020 (-0.26%)
Apr 24, 2026, 1:29 PM CET
Transgene Employees
Transgene had 145 employees as of December 31, 2025. The number of employees increased by 1 or 0.69% compared to the previous year.
Employees
145
Change (1Y)
1
Growth (1Y)
0.69%
Revenue / Employee
€49,724
Profits / Employee
€258,786
Market Cap
207.33M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 145 | 1 | 0.69% |
| Dec 31, 2024 | 144 | 3 | 2.13% |
| Dec 31, 2023 | 141 | -5 | -3.42% |
| Dec 31, 2022 | 146 | 3 | 2.10% |
| Dec 31, 2021 | 143 | 4 | 2.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Cellectis | 229 |
| Genfit | 188 |
| Innate Pharma | 174 |
| Adocia | 77 |
| MaaT Pharma | 65 |
| OSE Immunotherapeutics | 64 |
| Sensorion | 63 |
Transgene News
- 3 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire
- 3 years ago - Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration - Business Wire
- 3 years ago - Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022 - Business Wire
- 3 years ago - BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 - Accesswire
- 3 years ago - Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers - Business Wire
- 3 years ago - R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data - Business Wire
- 3 years ago - Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 - Business Wire